Should we focus on novel risk markers and screening tests to better predict and prevent cardiovascular disease?

Preventive Cardiology

Volumn 13, Issue 4, 2010, Pages 152-159

  Enriquez, Jonathan R ^a   de Lemos, James A ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DISEASE MARKER; HUMAN; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR; SCREENING TEST;

ALGORITHMS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; HUMANS; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; TROPONIN;

EID: 77957161037     PISSN: 1520037X     EISSN: 17517141     Source Type: Journal    
DOI: 10.1111/j.1751-7141.2010.00080.x     Document Type: Article

References (38)

1. Wilson PW, D'Agostino RB, Levy D. Prediction of coronary heart disease using risk factor categories. Circulation 1998, 97:1837-1847.
2. Conroy RM, Pyorala K, Fitzgerald AP. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003, 24:987-1003.
3. Hippisley-Cox J, Coupland C, Vinogradova Y. Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study. BMJ 2007, 335:136.
4. Redberg RF, Benjamin EJ, Bittner V. ACCF/AHA 2009 performance measures for primary prevention of cardiovascular disease in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Performance Measures for Primary Prevention of Cardiovascular Disease) developed in collaboration with the American Academy of Family Physicians; American Association of Cardiovascular and Pulmonary Rehabilitation; and Preventive Cardiovascular Nurses Association: endorsed by the American College of Preventive Medicine, American College of Sports Medicine, and Society for Women's Health Research. J Am Coll Cardiol 2009, 54:1364-1405.
5. Grundy SM, Cleeman JI, Merz CN. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004, 110:227-239.
6. Orford JL, Sesso HD, Stedman M. A comparison of the Framingham and European Society of Cardiology coronary heart disease risk prediction models in the normative aging study. Am Heart J 2002, 144:95-100.
7. Ford ES, Giles WH, Mokdad AH. The distribution of 10-year risk for coronary heart disease among US adults: findings from the National Health and Nutrition Examination Survey III. J Am Coll Cardiol 2004, 43:1791-1796.
8. National Health and Nutrition Examination Survey Data 2010, Hyattsville, MD, U.S. Department of Health and Human Services, Centers for Disease Control and Prevention
9. Vasan RS, Sullivan LM, Wilson PW. Relative importance of borderline and elevated levels of coronary heart disease risk factors. Ann Intern Med 2005, 142:393-402.
10. Lloyd-Jones DM, Wilson PW, Larson MG. Framingham risk score and prediction of lifetime risk for coronary heart disease. Am J Cardiol 2004, 94:20-24.
11. Berry JD, Garside DB, Cai X. Remaining lifetime risks for cardiovascular disease death by risk factor burden at selected ages in black and white men and women. Circulation 2007, 116:832.
12. Cook NR. Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation 2007, 115:928-935.
13. Danesh J, Wheeler JG, Hirschfield GM. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004, 350:1387-1397.
14. Kaptoge S, Di Angelantonio E, Lowe G. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 2010, 375:132-140.
15. Kistorp C, Raymond I, Pedersen F. N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. JAMA 2005, 293:1609-1616.
16. Rutten JH, Mattace-Raso FU, Steyerberg EW. Amino-terminal pro-B-type natriuretic peptide improves cardiovascular and cerebrovascular risk prediction in the population: the Rotterdam study. Hypertension 2010, 55:785-791.
17. Di Angelantonio E, Chowdhury R, Sarwar N. B-type natriuretic peptides and cardiovascular risk: systematic review and meta-analysis of 40 prospective studies. Circulation 2009, 120:2177-2187.
18. Wallace TW, Abdullah SM, Drazner MH. Prevalence and determinants of troponin T elevation in the general population. Circulation 2006, 113:1958-1965.
19. Zethelius B, Johnston N, Venge P. Troponin I as a predictor of coronary heart disease and mortality in 70-year-old men: a community-based cohort study. Circulation 2006, 113:1071-1078.
20. Daniels LB, Laughlin GA, Clopton P. Minimally elevated cardiac troponin T and elevated N-terminal pro-B-type natriuretic peptide predict mortality in older adults: results from the Rancho Bernardo Study. J Am Coll Cardiol 2008, 52:450-459.
21. Latini R, Masson S, Anand IS. Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure. Circulation 2007, 116:1242-1249.
22. Omland T, de Lemos JA, Sabatine MS. A sensitive cardiac troponin T assay in stable coronary artery disease. N Engl J Med 2009, 361:2538-2547.
23. Blankenberg S, McQueen MJ, Smieja M. Comparative impact of multiple biomarkers and N-Terminal pro-brain natriuretic peptide in the context of conventional risk factors for the prediction of recurrent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation 2006, 114:201-208.
24. Wang TJ, Gona P, Larson MG. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med 2006, 355:2631-2639.
25. Cook NR. Statistical evaluation of prognostic versus diagnostic models: beyond the ROC curve. Clin Chem 2008, 54:17-23.
26. Zethelius B, Berglund L, Sundstrom J. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med 2008, 358:2107-2116.
27. de Lemos JA, Rohatgi A. Separating the contenders from the pretenders: competitive high-throughput biomarker screening in large population-based studies. Circulation 2010, 121:2381-2383.
28. Melander O, Newton-Cheh C, Almgren P. Novel and conventional biomarkers for prediction of incident cardiovascular events in the community. JAMA 2009, 302:49-57.
29. Blankenberg S, Zeller T, Saarela O. Contribution of 30 biomarkers to 10-year cardiovascular risk estimation in 2 population cohorts: the MONICA, risk, genetics, archiving, and monograph (MORGAM) biomarker project. Circulation 2010, 121:2388-2397.
30. Wong ND, Detrano RC, Diamond G. Does coronary artery screening by electron beam computed tomography motivate potentially beneficial lifestyle behaviors? Am J Cardiol 1996, 78:1220-1223.
31. Janowitz WR, Agatston AS, Viamonte M. Comparison of serial quantitative evaluation of calcified coronary artery plaque by ultrafast computed tomography in persons with and without obstructive coronary artery disease. Am J Cardiol 1991, 68:1-6.
32. Budoff MJ, Georgiou D, Brody A. Ultrafast computed tomography as a diagnostic modality in the detection of coronary artery disease: a multicenter study. Circulation 1996, 93:898-904.
33. Detrano R, Guerci AD, Carr JJ. Coronary calcium as a predictor of coronary events in four racial or ethnic groups. N Engl J Med 2008, 358:1336-1345.
34. Polonsky TS, McClelland RL, Jorgensen NW. Coronary artery calcium score and risk classification for coronary heart disease prediction. JAMA 2010, 303:1610-1616.
35. Wilson PW, Pencina M, Jacques P. C-reactive protein and reclassification of cardiovascular risk in the Framingham Heart Study. Circ Cardiovasc Qual Outcomes 2008, 1:92-97.
36. Cook NR. Comments on 'Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond' by MJ Pencina et al., Statistics in Medicine (DOI: 10.1002/sim.2929). Stat Med 2008, 27:191-195.
37. Morrow DA, de Lemos JA. Benchmarks for the assessment of novel cardiovascular biomarkers. Circulation 2007, 115:949-952.
38. Shah SH, de Lemos JA. Biomarkers and cardiovascular disease: determining causality and quantifying contribution to risk assessment. JAMA 2009, 302:92-93.